AbbVie Inc. 's ABBV announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie's multi-utility TNF blocker drug, Humira. With this ...

The safety and efficacy of Humira in patients with moderate to severe fingernail psoriasis and moderate to severe chronic plaque psoriasis was evaluated in a Phase 3, multicenter, double-blind, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has approved including ...

NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to ...

HUMIRA Receives FDA Approval For Treatment of Crohn's Disease ABBOTT PARK, IL, USA -- Abbott announced today it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA(R) ...

Abbott has submitted an application for approval of HUMIRA for plaque psoriasis, and is also developing HUMIRA in Japan for Crohn's disease, ankylosing spondylitis, juvenile rheumatoid arthritis and ...

Recent FDA actions have included approving Juvéderm Vollure XC for treating nasolabial folds with results up to 18 months and the addition of fingernail psoriasis ...

Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...

The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion USA, announced today. It ...

If you’re like most people, you never heard of the prescription drug Humira until 2013. That’s when Abbott Laboratories spun off AbbVie, to aggressively market the rheumatoid arthritis (RA) drug which ...